Volitionrx Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Volitionrx has an operating margin of -2190.9%, meaning the company retains $-2191 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -4641.8% the prior year.
Volitionrx's revenue surged 59.1% year-over-year to $1.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Volitionrx's current ratio of 0.52 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 1/100, which could limit financial flexibility.
While Volitionrx generated -$25.9M in operating cash flow, capex of $277K consumed most of it, leaving -$26.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Volitionrx passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Volitionrx generates $0.95 in operating cash flow (-$25.9M OCF vs -$27.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Volitionrx (VNRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Volitionrx generated $1.2M in revenue in fiscal year 2024. This represents an increase of 59.1% from the prior year.
Volitionrx's EBITDA was -$25.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.6% from the prior year.
Volitionrx generated -$26.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 36.7% from the prior year.
Volitionrx reported -$27.3M in net income in fiscal year 2024. This represents an increase of 23.6% from the prior year.
Volitionrx earned $-0.31 per diluted share (EPS) in fiscal year 2024. This represents an increase of 38.0% from the prior year.
Volitionrx held $3.3M in cash against $4.0M in long-term debt as of fiscal year 2024.
Volitionrx had 96M shares outstanding in fiscal year 2024. This represents an increase of 17.3% from the prior year.
Volitionrx's operating margin was -2190.9% in fiscal year 2024, reflecting core business profitability. This is up 2450.9 percentage points from the prior year.
Volitionrx's net profit margin was -2209.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2391.9 percentage points from the prior year.
Volitionrx invested $14.4M in research and development in fiscal year 2024. This represents a decrease of 26.3% from the prior year.
Volitionrx spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Volitionrx invested $277K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 74.4% from the prior year.
VNRX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $627K+54.2% | $407K+65.1% | $246K+28.6% | $192K-51.6% | $396K+130.7% | $172K-29.7% | $244K+47.7% | $165K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.3M-16.0% | $2.7M+4.3% | $2.6M+0.8% | $2.6M-30.4% | $3.7M-19.7% | $4.6M+1.9% | $4.5M-2.3% | $4.7M |
| SG&A Expenses | $2.5M-15.5% | $2.9M+31.1% | $2.2M+5.1% | $2.1M-6.6% | $2.3M+1.3% | $2.3M-11.3% | $2.5M-2.2% | $2.6M |
| Operating Income | -$5.1M+19.0% | -$6.3M-14.1% | -$5.5M+4.5% | -$5.8M+17.3% | -$7.0M+16.6% | -$8.4M+4.1% | -$8.7M-1.0% | -$8.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.4M+14.4% | -$6.3M-15.9% | -$5.4M+10.8% | -$6.1M+12.9% | -$7.0M+16.5% | -$8.4M+4.9% | -$8.8M-4.1% | -$8.5M |
| EPS (Diluted) | $-0.05+16.7% | $-0.060.0% | $-0.060.0% | $-0.06+25.0% | $-0.08+20.0% | $-0.10 | N/A | N/A |
VNRX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.4M-25.9% | $8.7M+2.2% | $8.5M-9.4% | $9.4M-28.1% | $13.1M-32.8% | $19.4M-30.5% | $28.0M+54.9% | $18.0M |
| Current Assets | $1.3M-59.2% | $3.3M-0.9% | $3.3M-18.8% | $4.1M-44.8% | $7.3M-45.5% | $13.5M-38.4% | $21.9M+79.2% | $12.2M |
| Cash & Equivalents | $200K-91.3% | $2.3M-11.5% | $2.6M-20.4% | $3.3M-45.6% | $6.0M-49.0% | $11.8M-43.2% | $20.7M+91.8% | $10.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $309K+63.0% | $190K+0.9% | $188K+69.9% | $111K-33.5% | $166K+24.5% | $134K-45.0% | $243K+604.4% | $34K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $42.4M+1.4% | $41.8M+11.3% | $37.5M+5.7% | $35.5M-1.3% | $36.0M-0.2% | $36.1M-1.7% | $36.7M+75.5% | $20.9M |
| Current Liabilities | $11.4M+23.6% | $9.2M+11.7% | $8.3M+6.2% | $7.8M-74.8% | $31.0M-1.6% | $31.5M+252.1% | $8.9M-49.3% | $17.7M |
| Long-Term Debt | $5.6M-3.6% | $5.8M+4.3% | $5.5M+40.0% | $4.0M+2.3% | $3.9M+14.6% | $3.4M-7.0% | $3.6M+73.8% | $2.1M |
| Total Equity | -$34.6M-8.9% | -$31.8M-14.6% | -$27.8M-11.5% | -$24.9M-14.2% | -$21.8M-39.7% | -$15.6M-100.0% | -$7.8M-281.9% | -$2.0M |
| Retained Earnings | -$246.6M-2.2% | -$241.3M-2.7% | -$235.0M-2.4% | -$229.5M-5.3% | -$217.9M-3.3% | -$210.9M-4.1% | -$202.6M-4.5% | -$193.9M |
VNRX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.6M+42.0% | -$6.3M-45.7% | -$4.3M+20.9% | -$5.4M+19.3% | -$6.7M+19.3% | -$8.3M-229.4% | $6.4M+176.6% | -$8.4M |
| Capital Expenditures | $0-100.0% | $77K+4146.8% | $2K-97.5% | $73K+84.5% | $39K+36.6% | $29K-90.7% | $309K+13.1% | $273K |
| Free Cash Flow | -$3.6M+42.7% | -$6.3M-47.4% | -$4.3M+21.9% | -$5.5M+18.7% | -$6.8M+19.1% | -$8.4M-236.4% | $6.1M+170.6% | -$8.7M |
| Investing Cash Flow | $0+100.0% | -$77K-4146.8% | -$2K+99.1% | -$198K-23.3% | -$160K-103.6% | -$79K+74.5% | -$309K-13.1% | -$273K |
| Financing Cash Flow | $1.6M-71.8% | $5.7M+54.6% | $3.7M+60.1% | $2.3M+135.2% | $973K+564.9% | -$209K-105.6% | $3.8M+1472.3% | -$275K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 |
VNRX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -813.2%+735.4pp | -1548.6%+692.5pp | -2241.1%+775.4pp | -3016.5%-1250.3pp | -1766.2%+3121.8pp | -4887.9%-1305.3pp | -3582.6%+1655.0pp | -5237.6% |
| Net Margin | -857.4%+687.8pp | -1545.2%+656.2pp | -2201.3%+972.8pp | -3174.2%-1409.2pp | -1764.9%+3113.0pp | -4877.9%-1271.1pp | -3606.8%+1509.8pp | -5116.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -83.4%-11.2pp | -72.2%-8.5pp | -63.7%+1.1pp | -64.7%-11.3pp | -53.5%-10.4pp | -43.0%-11.6pp | -31.5%+15.4pp | -46.9% |
| Current Ratio | 0.12-0.2 | 0.35-0.0 | 0.40-0.1 | 0.52+0.3 | 0.24-0.2 | 0.43-2.0 | 2.44+1.8 | 0.69 |
| Debt-to-Equity | -0.16+0.0 | -0.18+0.0 | -0.20-0.0 | -0.16+0.0 | -0.18+0.0 | -0.22+0.2 | -0.46+0.6 | -1.02 |
| FCF Margin | -578.8%+980.0pp | -1558.8%+186.4pp | -1745.2%+1126.8pp | -2872.0%-1161.2pp | -1710.8%+3169.3pp | -4880.2%-7396.4pp | 2516.3%+7777.1pp | -5260.8% |
Note: Shareholder equity is negative (-$24.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.52), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Volitionrx's annual revenue?
Volitionrx (VNRX) reported $1.2M in total revenue for fiscal year 2024. This represents a 59.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Volitionrx's revenue growing?
Volitionrx (VNRX) revenue grew by 59.1% year-over-year, from $775K to $1.2M in fiscal year 2024.
Is Volitionrx profitable?
No, Volitionrx (VNRX) reported a net income of -$27.3M in fiscal year 2024, with a net profit margin of -2209.8%.
What is Volitionrx's earnings per share (EPS)?
Volitionrx (VNRX) reported diluted earnings per share of $-0.31 for fiscal year 2024. This represents a 38.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Volitionrx's EBITDA?
Volitionrx (VNRX) had EBITDA of -$25.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Volitionrx have?
As of fiscal year 2024, Volitionrx (VNRX) had $3.3M in cash and equivalents against $4.0M in long-term debt.
What is Volitionrx's operating margin?
Volitionrx (VNRX) had an operating margin of -2190.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Volitionrx's net profit margin?
Volitionrx (VNRX) had a net profit margin of -2209.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Volitionrx's free cash flow?
Volitionrx (VNRX) generated -$26.2M in free cash flow during fiscal year 2024. This represents a -36.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Volitionrx's operating cash flow?
Volitionrx (VNRX) generated -$25.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Volitionrx's total assets?
Volitionrx (VNRX) had $9.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Volitionrx's capital expenditures?
Volitionrx (VNRX) invested $277K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Volitionrx spend on research and development?
Volitionrx (VNRX) invested $14.4M in research and development during fiscal year 2024.
How many shares does Volitionrx have outstanding?
Volitionrx (VNRX) had 96M shares outstanding as of fiscal year 2024.
What is Volitionrx's current ratio?
Volitionrx (VNRX) had a current ratio of 0.52 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Volitionrx's debt-to-equity ratio?
Volitionrx (VNRX) had a debt-to-equity ratio of -0.16 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Volitionrx's return on assets (ROA)?
Volitionrx (VNRX) had a return on assets of -290.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Volitionrx's cash runway?
Based on fiscal year 2024 data, Volitionrx (VNRX) had $3.3M in cash against an annual operating cash burn of $25.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Volitionrx's debt-to-equity ratio negative or unusual?
Volitionrx (VNRX) has negative shareholder equity of -$24.9M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Volitionrx's Piotroski F-Score?
Volitionrx (VNRX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Volitionrx's earnings high quality?
Volitionrx (VNRX) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Volitionrx?
Volitionrx (VNRX) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.